These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 32244015)

  • 1. Systematic retrospective study of 64 patients with anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy.
    Monseau G; Landon-Cardinal O; Stenzel W; Schoindre Y; Mariampillai K; Barete S; Martel C; Masseau A; Meyer A; Terrier B; Guégan S; Verneuil L; Audia S; Livideanu CB; Hachulla E; Kahn JE; Lefevre G; Maurier F; Moulis G; Papo T; Dossier A; Descamps V; Salort-Campana E; Richard MA; Bergot E; Mortier L; Costedoat-Chalumeau N; Genot S; Perez F; Piette AM; Samson M; Schleinitz N; Zénone T; Lacoste M; de Boysson H; Madaule S; Rigolet A; Champtiaux N; Hervier B; Bouvier AM; Jooste V; Léonard-Louis S; Maisonobe T; Aouba A; Benveniste O; Bienvenu B; Allenbach Y;
    J Am Acad Dermatol; 2020 Dec; 83(6):1759-1763. PubMed ID: 32244015
    [No Abstract]   [Full Text] [Related]  

  • 2. More prominent muscle involvement in patients with dermatomyositis with anti-Mi2 autoantibodies.
    Pinal-Fernandez I; Mecoli CA; Casal-Dominguez M; Pak K; Hosono Y; Huapaya J; Huang W; Albayda J; Tiniakou E; Paik JJ; Johnson C; Danoff SK; Corse AM; Christopher-Stine L; Mammen AL
    Neurology; 2019 Nov; 93(19):e1768-e1777. PubMed ID: 31594859
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Severe muscle damage with myofiber necrosis and macrophage infiltrates characterize anti-Mi2 positive dermatomyositis.
    Fornaro M; Girolamo F; Cavagna L; Franceschini F; Giannini M; Amati A; Lia A; Tampoia M; D'Abbicco D; Maggi L; Fredi M; Zanframundo G; Moschetti L; Coladonato L; Iannone F
    Rheumatology (Oxford); 2021 Jun; 60(6):2916-2926. PubMed ID: 33249503
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acquired Partial Lipodystrophy Associated with Anti-Mi-2 Antibody-positive Adult-onset Dermatomyositis.
    Shiraishi K; Tohyama M; Sayama K
    Acta Derm Venereol; 2019 Jan; 99(1):95-96. PubMed ID: 30182133
    [No Abstract]   [Full Text] [Related]  

  • 5. Autoantibodies in polymyositis and dermatomyositis.
    Ghirardello A; Bassi N; Palma L; Borella E; Domeneghetti M; Punzi L; Doria A
    Curr Rheumatol Rep; 2013 Jun; 15(6):335. PubMed ID: 23591825
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dermatomyositis: Clinical features and pathogenesis.
    DeWane ME; Waldman R; Lu J
    J Am Acad Dermatol; 2020 Feb; 82(2):267-281. PubMed ID: 31279808
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Specific autoantibodies in dermatomyositis: a helpful tool to classify different clinical subsets.
    Merlo G; Clapasson A; Cozzani E; Sanna L; Pesce G; Bagnasco M; Burlando M; Parodi A
    Arch Dermatol Res; 2017 Mar; 309(2):87-95. PubMed ID: 27928683
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical characteristics of four myositis-specific autoantibodies with regulatory-approved testing in Japan: A Japanese multi-centre adult myositis patients' cohort.
    Ueda-Hayakawa I; Fujimoto M; Sato S; Murakami A; Kawakami A; Mishima M; Seishima M; Suda T; Takehara K; Mimori T; Kuwana M
    J Dermatol Sci; 2021 Jul; 103(1):53-56. PubMed ID: 34088590
    [No Abstract]   [Full Text] [Related]  

  • 9. Autoantibodies in children with juvenile dermatomyositis: A single centre experience from North-West India.
    Hussain A; Rawat A; Jindal AK; Gupta A; Singh S
    Rheumatol Int; 2017 May; 37(5):807-812. PubMed ID: 28331982
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical and serological characteristics of 125 Dutch myositis patients. Myositis specific autoantibodies aid in the differential diagnosis of the idiopathic inflammatory myopathies.
    Hengstman GJ; Brouwer R; Egberts WT; Seelig HP; Jongen PJ; van Venrooij WJ; van Engelen BG
    J Neurol; 2002 Jan; 249(1):69-75. PubMed ID: 11954871
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies.
    Pinal-Fernandez I; Milisenda JC; Pak K; Muñoz-Braceras S; Casal-Dominguez M; Torres-Ruiz J; Dell'Orso S; Naz F; Gutierrez-Cruz G; Duque-Jaimez Y; Matas-Garcia A; Padrosa J; Garcia-Garcia FJ; Guitart-Mampel M; Garrabou G; Trallero-Araguás E; Walitt B; Paik JJ; Albayda J; Christopher-Stine L; Lloyd TE; Grau-Junyent JM; Selva-O'Callaghan A; Mammen AL
    Ann Rheum Dis; 2023 Aug; 82(8):1091-1097. PubMed ID: 37130727
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Myositis autoantibodies.
    Casciola-Rosen L; Mammen AL
    Curr Opin Rheumatol; 2012 Nov; 24(6):602-8. PubMed ID: 22955022
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Redefining dermatomyositis: a description of new diagnostic criteria that differentiate pure dermatomyositis from overlap myositis with dermatomyositis features.
    Troyanov Y; Targoff IN; Payette MP; Raynauld JP; Chartier S; Goulet JR; Bourré-Tessier J; Rich E; Grodzicky T; Fritzler MJ; Joyal F; Koenig M; Senécal JL
    Medicine (Baltimore); 2014 Nov; 93(24):318-332. PubMed ID: 25500701
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dermatomyositis: Diagnosis and treatment.
    Waldman R; DeWane ME; Lu J
    J Am Acad Dermatol; 2020 Feb; 82(2):283-296. PubMed ID: 31279813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy".
    Lim J; Raaphorst J; van der Kooi AJ
    J Am Acad Dermatol; 2020 Dec; 83(6):e459-e460. PubMed ID: 32758632
    [No Abstract]   [Full Text] [Related]  

  • 16. Autoantibody profiles in patients' sera associated with distribution patterns of dermatomyositis skin symptoms.
    Ogawa-Momohara M; Kinoshita F; Muro Y; Kobayashi Y; Takeichi T; Akiyama M
    J Am Acad Dermatol; 2021 Jun; 84(6):1720-1722. PubMed ID: 33867178
    [No Abstract]   [Full Text] [Related]  

  • 17. Response to: Comment on "Systematic retrospective study on 64 patients anti-Mi2 dermatomyositis: A classic skin rash with a necrotizing myositis and high risk of malignancy".
    Monseau G; Landon-Cardinal O; Bouvier AM; Jooste V; Aouba A; Bienvenu B; Benveniste O; Allenbach Y;
    J Am Acad Dermatol; 2020 Dec; 83(6):e461-e462. PubMed ID: 32758631
    [No Abstract]   [Full Text] [Related]  

  • 18. Myositis-specific autoantibodies and their association with malignancy in Italian patients with polymyositis and dermatomyositis.
    Ceribelli A; Isailovic N; De Santis M; Generali E; Fredi M; Cavazzana I; Franceschini F; Cantarini L; Satoh M; Selmi C
    Clin Rheumatol; 2017 Feb; 36(2):469-475. PubMed ID: 27761751
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Development of a New Classification System for Idiopathic Inflammatory Myopathies Based on Clinical Manifestations and Myositis-Specific Autoantibodies.
    Mariampillai K; Granger B; Amelin D; Guiguet M; Hachulla E; Maurier F; Meyer A; Tohmé A; Charuel JL; Musset L; Allenbach Y; Benveniste O
    JAMA Neurol; 2018 Dec; 75(12):1528-1537. PubMed ID: 30208379
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The clinical features, diagnosis and classification of dermatomyositis.
    Iaccarino L; Ghirardello A; Bettio S; Zen M; Gatto M; Punzi L; Doria A
    J Autoimmun; 2014; 48-49():122-7. PubMed ID: 24467910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.